| Popis: |
Objective To explore the clinical efficacy and safety of secukinumab in the treatment of childhood generalized pustular psoriasis (GPP) in order to provide a new therapeutic strategy for childhood generalized pustular psoriasis. Methods A retrospective analysis was conducted on the clinical data of 25 children with GPP treated with subcutaneous secukinumab in our department from June 2020 to June 2022. The efficacy was evaluated according to Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scores, Generalized Pustular Psoriasis Area and Severity Index (GPPASI) scores, Children's Dermatology Life Quality Index (CDLQI) scores, and Depression Self-rating Scale for children (DSRSC) scores. The adverse reactions were also assessed. Results Following secukinumab treatments, the average time of lesion clearance was 3.36±0.99 days. Alleviations of scales and pustules were observed in majority of patients after 2-week treatment. After 28-week treatment, GPPGA score was reduced from 3.56±0.50 at baseline to 0.20±0.50, while GPPASI score was decreased from 34.83±9.24 at baseline to 0.68±1.64. Similarly, both CDLQI and DSRSC scores were decreased 14.96±4.88 to 0.40±0.64 and 11.41±2.54 to 6.64±1.80, respectively. During the course of treatment, upper respiratory tract infections and eczema were observed in 2 cases each. One case each had pain with pruritus on the injection site and headache. No other adverse events were observed. Conclusions Secukinumab is safe and can rapidly improve the erythema, scales and pustules in pediatric generalized pustular psoriasis in addition to the improvements in patients' quality of life and mental health. |
